Headlines about Hutchison China MediTech (NASDAQ:HCM) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hutchison China MediTech earned a news impact score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3823942918904 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several equities analysts recently issued reports on the company. BidaskClub raised Hutchison China MediTech from a “hold” rating to a “buy” rating in a research report on Wednesday, September 6th. Canaccord Genuity upped their target price on Hutchison China MediTech to $38.00 and gave the company a “buy” rating in a research report on Monday, October 16th.
Hutchison China MediTech (NASDAQ HCM) traded up $3.01 during midday trading on Friday, hitting $36.97. The company had a trading volume of 119,271 shares, compared to its average volume of 95,590. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.73 and a current ratio of 1.84. Hutchison China MediTech has a 52-week low of $12.62 and a 52-week high of $37.09.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.